Topiramate Tablet
Product Images NDC 70518-2391

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70518-2391). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Topiramate is a medication that is available in a pack of 30 HD3. It is a prescription drug and is manufactured by Cipla USA, Inc., Miami. The medication should be kept out of the reach of children and must be stored at temperatures between 20-26°C. The directions for use are available in the package insert. The medication has been repackaged by RemedyRepack Inc., Indiana.*

FDA Label Image

Mm5 (Topiramate 200mg 70518 2391 01)

Topiramate is a prescription drug that is provided in a single HD3 quantity. It is NDC# 70518-2391-01 and is only available with a doctor's prescription. The drug has been manufactured by Cipla USA, Inc., located in Miami, FL 33156. The package insert contains guidelines for usage and should be followed carefully. The drug should be stored between 20-26°C (63-77°F) but can be kept at temperatures between 15-30°C (59-86°F) [See USP]. RemedyRepack Inc., located in Indiana, PA 15701, 724.466.8762 has repackaged the drug, and it should be kept out of the reach of children.*

FDA Label Image

Topiramate 200mg 70518 2391 02

Topiramate is a prescription drug that comes in a pack of 30 HD3 pills. The medication is manufactured by Cipla USA, Inc., Miami, FL 33156 and repackaged by RemedyRepack Inc., Indiana, PA 15701. The NDC number for this medication is 70518-2391-02 and the source NDC is 63097-0125-15. The expiration date and lot number are not available. The medication should be stored at 20-26°C (63-77°F) with excursions permitted to 15-30°C (59-86°F) [See USP]. Directions for use should be obtained from the package insert. Keep this and all medication out of the reach of children.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02

This appears to be a graph showing cumulative rates for time to first seizure in relation to Topiramate dosage over a period of time, with the dosages being 50mg/day and 400mg/day. The graph plots time (in days) on the x-axis and cumulative rates on the y-axis.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03

The text describes the change in the average monthly migraine period rate during a double-blind study phase for two different doses of a medication called TOPAMAX. The doses were 100 and 200 milligrams per day. The results showed a significant decrease in migraine frequency, with the higher dose demonstrating a greater reduction. The statistical significance of the findings is also indicated by the p-values.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.